Journal of International Oncology››2019,Vol. 46››Issue (2): 105-108.doi:10.3760/cma.j.issn.1673-422X.2019.02.010

Previous ArticlesNext Articles

Treatment of non-small cell lung cancer with EGFR-TKI

Long Lili1, Liang Yanling2, Zhang Xingmei2, Shi Yusheng3

  1. 1First Clinical Medical College of Southern Medical University, Guangzhou 510515, China; 2Department of Neurobiology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China; 3Department of Radiotherapy, Southern Hospital, Southern Medical University, Guangzhou 510515, China
  • Online:2019-02-08Published:2019-04-03
  • Contact:Shi Yusheng, Email: zxmray@gmail.com E-mail:zxmray@gmail.com
  • Supported by:

    National Natural Science Foundation of China (81871418)

Abstract:Epidermal growth factor receptortyrosine kinase inhibitors (EGFR-TKIs) are the key to the treatment of advanced nonsmall cell lung cancer (NSCLC), but there are various drugresistant mutations in the latter stage. The first and second generation of EGFRTKIs significantly prolong the survival of patients with EGFR-activated mutant tumors. The third generation of EGFR-TKIs effectively inhibit the progress of T790M mutant tumors. The fourth generation of EGFR-TKIs inhibit both L858R, T790M and L858R, T790M, C797S mutant tumors. Using circulating tumor DNA and exogenous RNA can effectively detect the mutation types of EGFR, and choose EGFR-TKIs therapy or combined chemotherapy according to the mutation types.

Key words:Carcinoma, non-small-cell lung,Receptor, epidermal growth factor,Molecular targeted therapy,Epidermal growth factor receptor-tyrosine kinase inhibitors,Drug resistance